BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 24361248)

  • 1. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
    Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
    Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
    Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
    J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
    Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
    Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
    Igawa S; Shirasawa M; Ozawa T; Nishinarita N; Okuma Y; Ono T; Sugimoto A; Kurahayashi S; Sugita K; Sone H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Thorac Cancer; 2018 Aug; 9(8):967-973. PubMed ID: 29870153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
    O'Brien ME; Konopa K; Lorigan P; Bosquee L; Marshall E; Bustin F; Margerit S; Fink C; Stigt JA; Dingemans AM; Hasan B; Van Meerbeeck J; Baas P
    Eur J Cancer; 2011 Oct; 47(15):2322-30. PubMed ID: 21684151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.
    Inoue A; Ishimoto O; Fukumoto S; Usui K; Suzuki T; Yokouchi H; Maemondo M; Kanbe M; Ogura S; Harada T; Oizumi S; Harada M; Sugawara S; Fukuhara T; Nukiwa T
    Ann Oncol; 2010 Apr; 21(4):800-803. PubMed ID: 19825887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Spigel DR; Hainsworth JD; Shipley DL; Mekhail TM; Zubkus JD; Waterhouse DM; Daniel DB; Burris HA; Greco FA
    Lung Cancer; 2018 Mar; 117():38-43. PubMed ID: 29496254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
    Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
    Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
    Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
    Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.